Holocene Advisors LP Acquires 167,078 Shares of Xenon Pharmaceuticals Inc. $XENE

Holocene Advisors LP boosted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 9.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,976,553 shares of the biopharmaceutical company’s stock after acquiring an additional 167,078 shares during the period. Holocene Advisors LP owned 2.56% of Xenon Pharmaceuticals worth $79,359,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of XENE. Wellington Management Group LLP grew its holdings in Xenon Pharmaceuticals by 66.0% in the third quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock worth $144,936,000 after purchasing an additional 1,435,096 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Xenon Pharmaceuticals by 1,294.2% during the second quarter. Geode Capital Management LLC now owns 970,343 shares of the biopharmaceutical company’s stock valued at $30,369,000 after purchasing an additional 900,746 shares during the last quarter. Braidwell LP boosted its position in shares of Xenon Pharmaceuticals by 33.0% in the 2nd quarter. Braidwell LP now owns 3,605,029 shares of the biopharmaceutical company’s stock worth $112,837,000 after purchasing an additional 895,154 shares in the last quarter. Commodore Capital LP grew its stake in shares of Xenon Pharmaceuticals by 30.1% in the 2nd quarter. Commodore Capital LP now owns 3,025,000 shares of the biopharmaceutical company’s stock worth $94,682,000 after buying an additional 700,000 shares during the last quarter. Finally, Vestal Point Capital LP increased its position in Xenon Pharmaceuticals by 53.8% during the 2nd quarter. Vestal Point Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock valued at $62,600,000 after buying an additional 700,000 shares in the last quarter. Institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Trading Down 1.0%

Shares of XENE opened at $54.66 on Tuesday. The company has a market cap of $4.55 billion, a price-to-earnings ratio of -12.54 and a beta of 0.91. The business’s fifty day simple moving average is $43.97 and its two-hundred day simple moving average is $42.07. Xenon Pharmaceuticals Inc. has a 12 month low of $26.74 and a 12 month high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same period in the previous year, the firm posted ($0.84) earnings per share. As a group, research analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Insiders Place Their Bets

In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 270,000 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $60.33, for a total transaction of $16,289,100.00. Following the transaction, the chief executive officer owned 6,000 shares in the company, valued at approximately $361,980. This represents a 97.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Andrea Difabio sold 2,607 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $60.11, for a total transaction of $156,706.77. Following the sale, the insider directly owned 4,893 shares in the company, valued at approximately $294,118.23. The trade was a 34.76% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 336,707 shares of company stock valued at $19,622,565. 4.07% of the stock is owned by insiders.

Wall Street Analyst Weigh In

XENE has been the subject of a number of recent research reports. Bank of America reiterated a “buy” rating on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Chardan Capital raised Xenon Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, November 19th. Wolfe Research initiated coverage on Xenon Pharmaceuticals in a report on Monday, February 23rd. They set an “outperform” rating and a $60.00 price target for the company. Wedbush lowered their price target on Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating for the company in a research report on Monday. Finally, Guggenheim reissued a “buy” rating and set a $90.00 price objective on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $71.88.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.